Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis

We evaluated the prognostic impact of clonal circulating plasma cells (cPCs) detected by six-color multi-parametric flow cytometry (MFC) in light chain (AL) amyloidosis at diagnosis. Of the 154 patients who underwent MFC, cPCs were detected in 42% ( n  = 65) patients. Median number of cPCs was 81 pe...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia 2018-06, Vol.32 (6), p.1421-1426
Main Authors: Sidana, Surbhi, Tandon, Nidhi, Dispenzieri, Angela, Gertz, Morie A., Dingli, David, Jevremovic, Dragan, Morice, William G., Kapoor, Prashant, Kourelis, Taxiarchis V., Lacy, Martha Q., Hayman, Suzanne R., Buadi, Francis K., Leung, Nelson, Go, Ronald S., Lin, Yi, Russell, Stephen J., Lust, John A., Zeldenrust, Steven R., Warsame, Rahma, Hwa, Yi L., Hobbs, Miriam, Fonder, Amie, Kyle, Robert A., Rajkumar, S. Vincent, Kumar, Shaji K., Gonsalves, Wilson I.
Format: Article
Language:English
Subjects:
13/31
631/67/1990/804
692/699/67/1990/804
Amyloidosis
Bone marrow
Cancer Research
Chains
Critical Care Medicine
Diagnosis
Flow cytometry
Hematology
Intensive
Internal Medicine
Medicine
Medicine & Public Health
Oncology
Patients
Plasma cells
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated the prognostic impact of clonal circulating plasma cells (cPCs) detected by six-color multi-parametric flow cytometry (MFC) in light chain (AL) amyloidosis at diagnosis. Of the 154 patients who underwent MFC, cPCs were detected in 42% ( n  = 65) patients. Median number of cPCs was 81 per 150,000 events (range: 6–17,844). High bone marrow plasma cell percentage was an independent predictor of presence of cPCs. Presence of cPCs at diagnosis was associated with inferior overall survival (OS) (90 vs. 98 months, p  = 0.003) and inferior progression free survival (PFS) (31 vs. 52 months, p  = 0.02). Estimated 1, 2 and 5 year OS in the two groups was: 74, 64 and 57 and 89, 87, and 80%, respectively. Estimated PFS at 1, 2, and 5 years was: 69, 56, and 23% and 80, 74, and 37%, respectively. Furthermore, the presence of cPCs at diagnosis was an independent adverse predictor of OS in multivariable analysis. Achieving a very-good partial response, or better, was able to overcome the adverse impact of cPCs at diagnosis. Patients with cPCs at diagnosis may warrant closer monitoring post-treatment, especially if they do not achieve a deep hematologic response.
ISSN:0887-6924
1476-5551
DOI:10.1038/s41375-018-0063-7